NCT05983146 is a Phase 1 clinical trial of HRS-7053 Injection in Advanced Malignant Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT05983146?

NCT05983146 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT05983146?

Interventions in NCT05983146: HRS-7053 Injection.

What condition does NCT05983146 study?

NCT05983146 studies Advanced Malignant Cancer.

Is NCT05983146 still recruiting?

NCT05983146 is currently withdrawn. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT05983146

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Withdrawn Phase 1 Last updated 24 July 2025

What this trial tests

Phase 1 trial testing HRS-7053 Injection in Advanced Malignant Cancer. Withdrawn.

Timeline

1 September 2023

Primary endpoint
30 May 2025

30 May 2025

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 September 2023
Primary completion	30 May 2025
Estimated completion	30 May 2025

Drugs / interventions tested

HRS-7053 Injection — full drug profile →

Conditions studied

Advanced Malignant Cancer — all drugs for Advanced Malignant Cancer →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and tolerability of multiple administration of HRS-7053 in patients with advanced malignancies Determine the maximum tolerated dose (MTD, if possible) and the recommended dose for Phase II clinical studies (RP2D)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05983146 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05983146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing